We previously developed TSLPRCART immunotherapy and reported potent preclinical in vitro and in vivo anti-leukemia activity in CRLF2-ovexpressing ALL cell lines and xenograft models [35]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.